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INTRODUCTION
Linezolid is the only member of the oxazolidi-
nones that is available for clinical use. It is a
synthetic antibiotic that, depending on the organ-
ism and the linezolid concentration, has a bac-
teriostatic or bactericidal effect by inhibiting
protein synthesis. Linezolid is relevant for
therapy of nosocomial pneumonia, community-
acquired pneumonia and complicated skin and
soft-tissue infections caused by staphylococci,
streptococci (including Streptococcus pneumoniae)
and enterococci, especially when these organisms
are resistant to other appropriate antimicrobial
agents. Linezolid is not active against Enterobac-
teriaceae, Pseudomonas spp., Acinetobacter spp.,
Haemophilus spp., Moraxella spp., Neisseria spp.
or anaerobic bacteria, and these organisms have
not been allocated breakpoints. Linezolid can be
administered orally or intravenously. This Tech-
nical Note is based on the linezolid rationale
document (available on the EUCAST website:
http://www.eucast.org). The rationale document
includes more details and published references
relating to the selection of EUCAST breakpoints.
DOSAGE
Clinical breakpoints have been determined for the
oral and intravenous use of linezolid 600 mg
twice-daily. No variations in linezolid dosing
have been noted among countries.
MIC DISTRIBUTIONS
The MICs of wild-type Staphylococcus aureus and
enterococci are £4 mg ⁄L, and for all coagulase-
negative staphylococci and streptococci are
£2 mg ⁄L.
ESTABLISHED BREAKPOINTS
Several of the European breakpoint committees
had established breakpoints before the establish-
ment of the EUCAST breakpoints, most com-
monly, sensitive (S) £4 ⁄ resistant (R) >4 mg ⁄L, but
in some cases S £2 ⁄R >4 mg ⁄L.
PHARMACOKINETIC DATA
Based on a standard oral or parenteral dose of
600 mg twice-daily, the pharmacokinetic data
used to evaluate linezolid are shown in Table 1.
Linezolid has high bioavailability, with similar
serum concentrations whether administered or-
ally or intravenously. Metabolites are inactive and
are excreted with unmetabolised drug in urine
and through the liver. The elimination half-life is
not influenced to any extent by renal function.
PHARMACODYNAMIC DATA
Linezolid is predominantly bacteriostatic with
some persistent antibiotic effects. Studies in ani-
mals indicate that the AUC ⁄MIC is the dominant
Table 1. Pharmacokinetic data for linezolid
Parameter
Data for intravenous
administration
Data for oral
administration
Dosage 600 mg · 2 IV 600 mg · 2 oral
Cmax (mg ⁄L) 15–20 15–20
Cmin (mg ⁄L) 6 4
Total body clearance (L ⁄h) 4.5–8.5 4.5–8.5
T1 ⁄ 2 (h), mean (range) 4.5–5.5 4.5–5.5
AUC24 h (mg.h ⁄L) 200–275 200–275
Fraction unbound (%) 69 69
Volume of distribution (L) 0.7–0.8 0.7–0.8
IV, intravenous.
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pharmacodynamic index. The pharmacodynamic
targets for AUC ⁄MIC for staphylococci are shown
in Table 2. As linezolid is bacteriostatic against
staphylococci, a bactericidal AUC ⁄MIC ratio tar-
get is not appropriate. Monte Carlo simulations
and target attainment rates for linezolid 600 mg
twice-daily are shown in Table 3. Such data
support a susceptible breakpoint of S £1 or
2 mg ⁄L.
CLINICAL EFFICACY
Randomised controlled clinical trials have shown
non-inferiority to established therapies for com-
munity-acquired pneumonia, hospital-acquired
pneumonia, and complicated skin and soft-tissue
infection.
BREAKPOINTS
Breakpoints are summarised in Table 4.
Non-species-related breakpoints
Non-species related breakpoints have been deter-
mined mainly on the basis of pharmacokinetic ⁄
pharmacodynamic data, and are independent of
MIC distributions for specific species. These
are for use only with species not mentioned
in Table 4, and not with those species for
which susceptibility testing is not recommended
(marked with ‘–‘ or ‘IE’ in EUCAST break-
point tables). The pharmacodynamic data
indicate non-species-related breakpoints of
S £2 ⁄R >4 mg ⁄L.
Table 2. Pharmacodynamic data for linezolid
Pharmacodynamic parameter Staphylococci
AUC ⁄MIC for bacteriostasis 80
AUC ⁄MIC from clinical data 100
Table 3. Monte Carlo simulation of target attainment for
linezolid 600 mg twice-daily
MIC
(mg ⁄L)
% target attainment at AUC ⁄MIC target of
50 75 100
0.12 100 100 100
0.25 100 100 100
0.50 100 100 100
1 100 100 100
2 100 87 83
4 75 49 42
8 0 0 0
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Species-related breakpoints
Breakpoints of S £2 ⁄R >4 mg ⁄L render wild-type
streptococci susceptible to linezolid. For staphy-
lococci and enterococci, the susceptible break-
point was increased to £4 mg ⁄L to avoid dividing
the wild-type MIC distributions. Strains with
MICs above the resistant breakpoint are rare.
The identification and susceptibility tests for any
such isolate must be repeated, and if the result is
confirmed, the isolate should be sent to a refer-
ence laboratory. Until there is evidence regarding
clinical response, such isolates should be reported
as resistant.
Species without breakpoints
Enterobacteriaceae, Pseudomonas spp., Acinetobact-
er spp., Haemophilus spp., Moraxella spp., Neisseria
spp. and anaerobic bacteria were considered poor
targets for linezolid therapy, and for that reason
were not allocated breakpoints.
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